CIPLA

's hitting its stride with the perfect mix of US specialty wins and steady India growth.

: Profits up 25% to ₹1,093 crores with US generics surging 32% shows they're finally capitalizing on their respiratory expertise and complex injectables. The gRevlimid launch and expanding respiratory pipeline are exactly the kind of niche plays that generate sustainable margins in the brutal US generics market. What's impressive is the 180 basis point margin expansion to 25.1% - that's not just volume growth, it's genuine operational improvement and product mix enhancement. India business growing 9% might sound modest, but it's consistent and profitable, providing the stable base their US bets need. The regulatory overhang is real though. FDA inspections at Goa and Indore facilities could derail momentum quickly if they find serious issues. And the gRevlimid windfall has an expiry date - competition will eventually erode those margins, probably by FY27. At 26x forward earnings, you're paying for continued execution on both pipeline launches and regulatory compliance. That's fair if they deliver, expensive if they stumble. Management's double-digit growth guidance for FY26 sounds achievable given current momentum, but pharma companies have a habit of over-promising on pipeline timing.